Darren Locke
Strong track record working within and with biopharma developing, optimizing, and validating immunohistochemistry (IHC) companion or complementary diagnostics... | Greater Philadelphia, Greater Philadelphia, United States
*50 free lookup(s) per month.
No credit card required.
Darren Locke’s Emails dl****@ak****.com
Darren Locke’s Phone Numbers No phone number available.
Social Media
Darren Locke’s Location Greater Philadelphia, Greater Philadelphia, United States
Darren Locke’s Expertise Strong track record working within and with biopharma developing, optimizing, and validating immunohistochemistry (IHC) companion or complementary diagnostics (CDx) for immuno-oncology programs - PD1 Keytruda/Merck, PD1 Nivolumab/BMS, Lag3 Relatlimab/BMS & Labcorp Leading efforts to bring multiplexed quantitative immunohistochemistry (mBF) and immunofluorescence (mIF) into biopharma clinical trials and used for FDA-approved IVD tests, including development of the first spatial biology CDx assays utilizing antibody-mediated multiplexing and cell phenotyping - Acrivon OncoSignature & NeraCare Immunoprint Strategic and functional oversight of multi-disciplinary contract research development services in CLIA certified high throughput laboratories, providing global clinical trial support delivering AI-derived signatures and tailored analysis plans for translational pathology and immunotherapy projects. Greater than 20 years of experience in oncology, cell and cancer biology.
Darren Locke’s Current Industry Akoya Biosciences
Darren
Locke’s Prior Industry
Royal Brompton And Harefield Trust Heart Science Center
|
The Institute Of Cancer Research
|
The Babraham Institute
|
University Of Pennsylvania
|
Rutgers New Jersey Medical School
|
Discovery Life Sciences
|
Bristol Myers Squibb
|
Cellcarta
|
Akoya Biosciences
|
Mability
Not the Darren Locke you were looking for?
Find accurate emails & phone numbers for over 700M professionals.
Work Experience
Akoya Biosciences
Consultant, Clinical Assay Development
Fri Dec 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Mability
Consultant
Sun Oct 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Akoya Biosciences
Senior Director, Advanced Biopharma Services Contract Lab
Thu Jun 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Dec 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Akoya Biosciences
Senior Director, Phenoptics Clinical Platform Prototyping and Applications
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Dec 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Akoya Biosciences
Senior Director, Clinical Assay Development
Thu Oct 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Dec 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Cellcarta
Senior Director, Global Assay Development Strategy
Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Oct 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Bristol Myers Squibb
Group Head
Fri Dec 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Bristol Myers Squibb
Associate Director
Wed Apr 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Discovery Life Sciences
Study Director
Fri Jan 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Mar 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Rutgers New Jersey Medical School
Instructor, Non-Tenure Track Faculty
Fri Feb 01 2002 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Oct 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
University Of Pennsylvania
Postdoctoral Research Fellow
Wed Mar 01 2000 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Feb 01 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
The Babraham Institute
Pre-Graduate Research
Wed Mar 01 1995 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Sep 01 1995 00:00:00 GMT+0000 (Coordinated Universal Time)
The Institute Of Cancer Research
Pre-Graduate Research
Tue Mar 01 1994 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Sep 01 1994 00:00:00 GMT+0000 (Coordinated Universal Time)
Royal Brompton And Harefield Trust Heart Science Center
Pre-Graduate Research
Mon Mar 01 1993 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Sep 01 1993 00:00:00 GMT+0000 (Coordinated Universal Time)Skills
Languages
Darren Locke Email Addresses
FAQ About Darren Locke
-
Darren Locke is located at
Greater Philadelphia, Greater Philadelphia, United States -
Darren Locke is a
Strong track record working within and with biopharma developing, optimizing, and validating immunohistochemistry (IHC) companion or complementary diagnostics (CDx) for immuno-oncology programs - PD1 Keytruda/Merck, PD1 Nivolumab/BMS, Lag3 Relatlimab/BMS & Labcorp Leading efforts to bring multiplexed quantitative immunohistochemistry (mBF) and immunofluorescence (mIF) into biopharma clinical trials and used for FDA-approved IVD tests, including development of the first spatial biology CDx assays utilizing antibody-mediated multiplexing and cell phenotyping - Acrivon OncoSignature & NeraCare Immunoprint Strategic and functional oversight of multi-disciplinary contract research development services in CLIA certified high throughput laboratories, providing global clinical trial support delivering AI-derived signatures and tailored analysis plans for translational pathology and immunotherapy projects. Greater than 20 years of experience in oncology, cell and cancer biology. Akoya Biosciences -
Darren Locke currently works in the
Akoya Biosciences -
Darren Locke specializes in
Strong track record working within and with biopharma developing, optimizing, and validating immunohistochemistry (IHC) companion or complementary diagnostics (CDx) for immuno-oncology programs - PD1 Keytruda/Merck, PD1 Nivolumab/BMS, Lag3 Relatlimab/BMS & Labcorp Leading efforts to bring multiplexed quantitative immunohistochemistry (mBF) and immunofluorescence (mIF) into biopharma clinical trials and used for FDA-approved IVD tests, including development of the first spatial biology CDx assays utilizing antibody-mediated multiplexing and cell phenotyping - Acrivon OncoSignature & NeraCare Immunoprint Strategic and functional oversight of multi-disciplinary contract research development services in CLIA certified high throughput laboratories, providing global clinical trial support delivering AI-derived signatures and tailored analysis plans for translational pathology and immunotherapy projects. Greater than 20 years of experience in oncology, cell and cancer biology. -
Darren Locke speaks the following languages:
No languages available. -
Darren Locke has prior experience in the following industries:
Akoya Biosciences , Akoya Biosciences , Akoya Biosciences , Akoya Biosciences , Cellcarta , Bristol Myers Squibb , Bristol Myers Squibb , Discovery Life Sciences , Rutgers New Jersey Medical School , University Of Pennsylvania , The Babraham Institute , The Institute Of Cancer Research , Royal Brompton And Harefield Trust Heart Science Center -
Darren Locke has the following professional experience:
Akoya Biosciences , Mability , Akoya Biosciences , Akoya Biosciences , Akoya Biosciences , Cellcarta , Bristol Myers Squibb , Bristol Myers Squibb , Discovery Life Sciences , Rutgers New Jersey Medical School , University Of Pennsylvania , The Babraham Institute , The Institute Of Cancer Research , Royal Brompton And Harefield Trust Heart Science Center . -
You can view Darren Locke’s
LinkedIn profile at LinkedIn URL. -
Darren Locke’s work email addresses are
[email protected] . -
Darren Locke works at
Akoya Biosciences
People you may be interested in
- Connie Liu
- Nitesh Goyal
- Ronette Wenberg
- Sabrina Cote
- Eric Uhrenholt
- Umesh Khan
- Jayana Jha
Sr. HR Manger at Baxter Healthcare
Quality Engg Manager at Optum
Own my own business at Cakes by Ron
Adjoint administratif
Design Manager
Sr. Associate at Wns Global Service Private Limited
Data service Associate at ServiceNow